Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

GS-US-546-5920 : A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia,Leukaemia

Trial Overview Read MoreRead more

This phase II trial is trying to understand how safe and well tolerated a new targeted cancer treatment is when combined with other standard treatments for people with leukaemia.
 

This trial is treating patients with Acute Myeloid Leukaemia.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies

Commercial Sponsor

Gilead Sciences, Inc.

Summary

Safety Run-in Cohort 1 (1L Unfit AML Mag+Ven+Aza) : Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab, venetoclax and azacitidine. THIS COHORT IS CLOSED FOR ENROLLMENT UNTIL FURTHER NOTICE. Biological: Magrolimab : Administered intravenously This study consists of 3 safety run-in cohorts;Safety Run-in Cohort 1 (1L Unfit AML Mag + Ven + Aza)Safety Run-in Cohort 2 (R/R AML Mag + MEC)Safety Run-in Cohort 3 (Post-chemo Maintenance Mag + CC-486)Participants will receive treatment at the assigned dose level for at least 4 cycles in the Safety Run-in cohorts, after which they may continue at the assigned dose level or switch to the RP2D upon agreement between the investigator and the sponsor. After completion of each safety run-in cohort and identification of the RP2D for that cohort, participants will be enrolled into the corresponding Phase 2 cohorts;Phase 2 Cohort 1 (1L Unfit UML Mag + Ven + Aza)Phase 2 Cohort 2 (R/R AML Mag + MEC)Phase 2 Cohort 3 (Post-chemo Maintenance Mag + CC-486)Cycle length is 28 days for both the Safety Run-in and Phase 2 cohorts.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next